NO981374L - Dendrittcellestimulerende faktor - Google Patents
Dendrittcellestimulerende faktorInfo
- Publication number
- NO981374L NO981374L NO981374A NO981374A NO981374L NO 981374 L NO981374 L NO 981374L NO 981374 A NO981374 A NO 981374A NO 981374 A NO981374 A NO 981374A NO 981374 L NO981374 L NO 981374L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- stimulating factor
- dendritic cell
- cell stimulating
- vivo
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 3
- 230000004936 stimulating effect Effects 0.000 title 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 abstract 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000001787 dendrite Anatomy 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53914295A | 1995-10-04 | 1995-10-04 | |
| PCT/US1996/015990 WO1997012633A1 (en) | 1995-10-04 | 1996-10-03 | Dendritic cell stimulatory factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO981374D0 NO981374D0 (no) | 1998-03-26 |
| NO981374L true NO981374L (no) | 1998-06-03 |
Family
ID=24149974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO981374A NO981374L (no) | 1995-10-04 | 1998-03-26 | Dendrittcellestimulerende faktor |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0871487B1 (xx) |
| JP (1) | JP3631496B2 (xx) |
| KR (2) | KR100514957B1 (xx) |
| CN (1) | CN1172718C (xx) |
| AT (1) | ATE432085T1 (xx) |
| AU (1) | AU697539B2 (xx) |
| BR (1) | BR9610802A (xx) |
| CA (1) | CA2232865A1 (xx) |
| CZ (1) | CZ97798A3 (xx) |
| DE (1) | DE69637942D1 (xx) |
| EA (1) | EA199800272A1 (xx) |
| EE (1) | EE9800105A (xx) |
| ES (1) | ES2323818T3 (xx) |
| IS (1) | IS4703A (xx) |
| LV (1) | LV12085B (xx) |
| NO (1) | NO981374L (xx) |
| NZ (1) | NZ321039A (xx) |
| PL (1) | PL187329B1 (xx) |
| RO (1) | RO120579B1 (xx) |
| SI (1) | SI9620116A (xx) |
| SK (1) | SK40898A3 (xx) |
| TR (1) | TR199800607T1 (xx) |
| WO (1) | WO1997012633A1 (xx) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US9068164B1 (en) * | 1995-02-02 | 2015-06-30 | Tristem Trading (Cyprus) Limited | Method of preparing an undifferentiated cell |
| NZ333607A (en) * | 1996-07-10 | 2000-08-25 | Immunex Corp | Method of stimulating the immune system by transfecting dendritic cells |
| AUPO388396A0 (en) * | 1996-11-27 | 1996-12-19 | Ludwig Institute For Cancer Research | Cellular adjuvant |
| WO1998057655A1 (en) * | 1997-06-17 | 1998-12-23 | Immunex Corporation | A method of enhancing antigen-specific peripheral immune tolerance |
| FR2775692B1 (fr) * | 1998-03-03 | 2000-06-16 | Roussy Inst Gustave | Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre |
| US6849452B1 (en) | 1998-03-03 | 2005-02-01 | Institut Gustave Roussy | Methods for activating natural killer (NK) cells and means for carrying out said methods |
| FR2782524B1 (fr) * | 1998-08-21 | 2002-07-19 | Roussy Inst Gustave | Methodes d'activation de cellules tueuses naturelles (nk) et moyens de mise en oeuvre |
| SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
| AU4423799A (en) * | 1998-06-04 | 1999-12-20 | Cornell Research Foundation Inc. | Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins |
| US6291661B1 (en) | 1998-07-02 | 2001-09-18 | Immunex Corporation | flt3-L mutants and method of use |
| AU5741699A (en) * | 1998-08-27 | 2000-03-21 | Universitatsklinikum Freiburg | Low-molecular fragments of hyaluronic acid for the preparation of vaccines |
| GB9827604D0 (en) * | 1998-12-15 | 1999-02-10 | Lorantis Ltd | Methods of immunosuppression |
| WO2001009303A2 (en) * | 1999-07-30 | 2001-02-08 | Vical Inc. | Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER |
| WO2001032204A2 (en) * | 1999-11-03 | 2001-05-10 | Powderject Vaccines, Inc. | Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| US6423539B2 (en) * | 2000-02-24 | 2002-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant treatment by in vivo activation of dendritic cells |
| AU5574001A (en) * | 2000-04-25 | 2001-11-07 | Immunex Corp | Method for treatment of tumors using photodynamic therapy |
| US20040247563A1 (en) * | 2000-11-02 | 2004-12-09 | Lynch David H. | Method of enhancing lymphocyte-mediated immune responses |
| AU2002225927A1 (en) * | 2000-11-17 | 2002-05-27 | Immunex Corporation | Chemoattractant recruitment of dendritic cells for enhancement of immunization |
| EP1441591B1 (en) * | 2001-09-06 | 2016-06-29 | NorthWest Biotherapeutics, Inc. | Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response |
| KR100490308B1 (ko) * | 2002-02-25 | 2005-05-17 | 크레아젠 주식회사 | 면역 치료용 성숙화된 수지상 세포 백신의 제조방법 |
| EP1487477A4 (en) * | 2002-03-26 | 2006-07-19 | Immunex Corp | METHOD OF USE OF FLT3 LIGAND IN IMMUNIZATION PROTOCOLS |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| KR100522526B1 (ko) * | 2002-11-28 | 2005-10-19 | 주식회사 바이넥스 | 면역 치료용 수지상 세포의 제조방법 |
| KR100614220B1 (ko) * | 2004-11-08 | 2006-08-21 | 고려대학교 산학협력단 | Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물 |
| DE102005016234B4 (de) * | 2005-04-08 | 2008-05-15 | Tgc Biomics Gmbh | Verfahren zur Einschleusung von exogenem Antigen in den MHC I-Präsentationsweg von Zellen |
| KR100818215B1 (ko) | 2006-10-11 | 2008-04-01 | 재단법인서울대학교산학협력재단 | Ｃｄ３４양성 줄기세포로부터 ｔ 임파구 전구체를 제조하는 방법 |
| KR101264811B1 (ko) | 2011-05-20 | 2013-05-15 | 충남대학교산학협력단 | 마이코박테리움 압세수스의 ＭＡＢ０９８１ｃ 단백질을 이용한 수지상 세포의 성숙방법 |
| US11850279B2 (en) | 2016-07-13 | 2023-12-26 | Ohio State Innovation Foundation | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US826250A (en) | 1905-12-20 | 1906-07-17 | Albert Huck | Switch for toy railways. |
| US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| EP0790307A1 (en) | 1986-12-16 | 1997-08-20 | Gist-Brocades B.V. | Molecular cloning and expression of human IL-3 |
| OA09736A (en) | 1987-02-18 | 1993-11-30 | Schering Biotech Corp | "Human interleukin-3 and muteins thereof". |
| JPH03502322A (ja) | 1987-10-30 | 1991-05-30 | イミュネックス・コーポレーション | ヒトコロニー形成刺激因子の非グリコシル化類似体 |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| US5108910A (en) | 1989-08-22 | 1992-04-28 | Immunex Corporation | DNA sequences encoding fusion proteins comprising GM-CSF and IL-3 |
| EP0676470A1 (en) | 1989-10-16 | 1995-10-11 | Amgen Inc. | Stem cell factor |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| DK0614485T3 (da) | 1991-10-23 | 2002-10-28 | Nexell Therapeutics Inc | Fremgangsmåde til selektiv formering af CD34 positive celler |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| NZ314644A (en) * | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
| US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
-
1996
- 1996-10-03 AT AT96936216T patent/ATE432085T1/de not_active IP Right Cessation
- 1996-10-03 WO PCT/US1996/015990 patent/WO1997012633A1/en not_active Application Discontinuation
- 1996-10-03 RO RO98-00824A patent/RO120579B1/ro unknown
- 1996-10-03 DE DE69637942T patent/DE69637942D1/de not_active Expired - Lifetime
- 1996-10-03 CA CA002232865A patent/CA2232865A1/en not_active Abandoned
- 1996-10-03 ES ES96936216T patent/ES2323818T3/es not_active Expired - Lifetime
- 1996-10-03 SI SI9620116A patent/SI9620116A/sl unknown
- 1996-10-03 AU AU73922/96A patent/AU697539B2/en not_active Ceased
- 1996-10-03 PL PL96325964A patent/PL187329B1/pl not_active IP Right Cessation
- 1996-10-03 SK SK408-98A patent/SK40898A3/sk unknown
- 1996-10-03 CN CNB96197351XA patent/CN1172718C/zh not_active Expired - Fee Related
- 1996-10-03 KR KR10-1998-0702286A patent/KR100514957B1/ko not_active IP Right Cessation
- 1996-10-03 EA EA199800272A patent/EA199800272A1/ru unknown
- 1996-10-03 KR KR1020047011434A patent/KR100676792B1/ko not_active IP Right Cessation
- 1996-10-03 EP EP96936216A patent/EP0871487B1/en not_active Expired - Lifetime
- 1996-10-03 EE EE9800105A patent/EE9800105A/xx unknown
- 1996-10-03 NZ NZ321039A patent/NZ321039A/en unknown
- 1996-10-03 BR BR9610802A patent/BR9610802A/pt unknown
- 1996-10-03 CZ CZ98977A patent/CZ97798A3/cs unknown
- 1996-10-03 JP JP51449097A patent/JP3631496B2/ja not_active Expired - Fee Related
- 1996-10-03 TR TR1998/00607T patent/TR199800607T1/xx unknown
-
1998
- 1998-03-26 NO NO981374A patent/NO981374L/no unknown
- 1998-03-26 IS IS4703A patent/IS4703A/is unknown
- 1998-04-02 LV LVP-98-63A patent/LV12085B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9610802A (pt) | 1999-07-13 |
| ES2323818T3 (es) | 2009-07-24 |
| AU7392296A (en) | 1997-04-28 |
| IS4703A (is) | 1998-03-26 |
| CN1172718C (zh) | 2004-10-27 |
| TR199800607T1 (xx) | 1998-06-22 |
| EP0871487A1 (en) | 1998-10-21 |
| AU697539B2 (en) | 1998-10-08 |
| NZ321039A (en) | 2001-03-30 |
| CA2232865A1 (en) | 1997-04-10 |
| KR20040079421A (ko) | 2004-09-14 |
| NO981374D0 (no) | 1998-03-26 |
| SK40898A3 (en) | 1999-04-13 |
| JPH11513389A (ja) | 1999-11-16 |
| KR19990063818A (ko) | 1999-07-26 |
| RO120579B1 (ro) | 2006-04-28 |
| KR100676792B1 (ko) | 2007-02-02 |
| PL187329B1 (pl) | 2004-06-30 |
| EP0871487B1 (en) | 2009-05-27 |
| DE69637942D1 (de) | 2009-07-09 |
| PL325964A1 (en) | 1998-08-17 |
| ATE432085T1 (de) | 2009-06-15 |
| SI9620116A (sl) | 1999-08-31 |
| CN1229359A (zh) | 1999-09-22 |
| WO1997012633A1 (en) | 1997-04-10 |
| EA199800272A1 (ru) | 1998-10-29 |
| LV12085A (lv) | 1998-07-20 |
| LV12085B (en) | 1998-09-20 |
| CZ97798A3 (cs) | 1999-02-17 |
| EP0871487A4 (en) | 2004-09-01 |
| EE9800105A (et) | 1998-10-15 |
| KR100514957B1 (ko) | 2005-11-25 |
| JP3631496B2 (ja) | 2005-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO981374L (no) | Dendrittcellestimulerende faktor | |
| GR3036951T3 (en) | Cells with multiple altered epitopes on a surface antigen for use in transplantation | |
| Baldwin et al. | Immunology of spontaneously arising rat mammary adenocarcinomas | |
| DE69533964D1 (de) | Orale immunisierung durch verwendung von transgenen pflanzen | |
| ATE195875T1 (de) | Spezifische modulationen des immunsystems | |
| Riggins et al. | Immunity to spontaneous and methylcholanthrene-induced tumors in inbred mice | |
| EP1690934A3 (en) | Generation of xenogeneic antibodies | |
| DK0871414T3 (da) | Fremgangsmåder til fremstilling af væv til implantering | |
| NZ322910A (en) | Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof | |
| JPS5533474A (en) | Vaccine and its manufacture | |
| Somani et al. | Reimmunization after allogeneic bone marrow transplantation | |
| DE60040672D1 (de) | Antikörper-abhängige vergrösserung der alphavirus-infektvität | |
| DE60130634D1 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
| ATE322540T1 (de) | Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender | |
| SE8205247D0 (sv) | Fiskvacciner | |
| Yefenof et al. | Nonimmunogenic radiation-induced lymphoma: Immunity induction by a somatic cell hybrid | |
| Seravalli | Isolation by isoelectric focusing of a mitogenic substance released by stimulated human lymphocytes | |
| Neri et al. | Influence of neuraminidase and mitomycin C on the immunogenicity of Novikoff tumor cells | |
| RUSSELL | Transplantation of tissues and organs | |
| London | Reovirus-induced perturbations of mucosal T and B lymphocyte populations. | |
| CHESTERMAN | THE object of this investigation was to confirm | |
| GB1346494A (en) | Production of vaccines against foot and mouth disease |